Key result
Nifekalant is a pure class III antiarrhythmic drug that effectively treats life-threatening ventricular tachycardia and fibrillation by blocking IKr without causing negative inotropic effects.
Why the study?
Does nifekalant effectively treat life-threatening ventricular arrhythmias in patients unresponsive to conventional therapies?
Does nifekalant effectively treat life-threatening ventricular arrhythmias in patients unresponsive to conventional therapies?
Nifekalant is a pure class III antiarrhythmic drug that effectively treats refractory ventricular arrhythmias without depressing cardiac function, though it requires monitoring for QT prolongation and TdP.
No takes yet. Share an insight, caveat, or question.
May support consideration for refractory VT/VF without inotropy concerns; leaves open confirmation by prospective RCTs.
Oyabe et al. (2002) conducted a review in Life-threatening arrhythmias (ventricular tachycardia and fibrillation). Nifekalant was evaluated. Nifekalant is a pure class III antiarrhythmic drug that effectively treats life-threatening ventricular tachycardia and fibrillation by blocking IKr without causing negative inotropic effects.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: